Related Experiment Video
Updated: Jun 24, 2025

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
Comparison of alpha-2 agonist versus alpha-1 antagonist for post-traumatic stress disorder-associated nightmares in
Seher Khalid1,2, Sandra Mitchell1, Cheryl Al-Mateen2
1Clinical Pharmacy Specialist, Child and Adolescent Psychiatry, Virginia Commonwealth University Health System Department, Richmond, Virginia.
Insights
Clonidine and guanfacine were effective for pediatric PTSD nightmares, similar to prazosin. Clonidine showed a faster reduction in nightmares compared to guanfacine in children with posttraumatic stress disorder (PTSD).
Area of Science:
- Pediatric Psychiatry
- Pharmacology
- Sleep Medicine
Background:
- Posttraumatic stress disorder (PTSD) in children and adolescents frequently co-occurs with sleep disturbances, particularly nightmares.
- Current treatments for pediatric PTSD-related nightmares often rely on extrapolations from adult studies.
- There is a need to evaluate specific pharmacologic interventions for this vulnerable population.
Purpose of the Study:
- To determine the effectiveness and safety of alpha-2 agonists (clonidine, guanfacine) versus an alpha-1 antagonist (prazosin) for treating PTSD-related nightmares in pediatric patients.
- To compare the efficacy and onset of action of clonidine and guanfacine within the alpha-2 agonist class.
Main Methods:
- Retrospective review of medical records for patients aged 5-17 years admitted to an inpatient psychiatric unit.
- Inclusion criteria: new initiation of clonidine, guanfacine, or prazosin with a diagnosis of PTSD or related disorders.
- Primary endpoint: percentage of patients experiencing a reduction in nightmare frequency.
Main Results:
- Both alpha-2 agonists and alpha-1 antagonists demonstrated high response rates in reducing nightmares (91.9% vs. 86.4%, respectively).
- No statistically significant difference in overall nightmare reduction between the two drug classes.
- Clonidine showed a significantly faster time to nightmare reduction (1.59 days) compared to guanfacine (3.18 days) (p=0.005).
Conclusions:
- Alpha-2 agonists (clonidine, guanfacine) and alpha-1 antagonists (prazosin) are effective treatments for pediatric PTSD-associated nightmares.
- Both medication classes exhibit a low incidence of adverse effects and a rapid onset of action.
- Clonidine may offer a quicker resolution of nightmares compared to guanfacine in this pediatric population.
Introduction:
Posttraumatic stress disorder (PTSD) in children and adolescents has a high prevalence of accompanying sleep disturbances. Currently, pediatric treatment of PTSD-related nightmares is extrapolated from adult studies. This study aims to determine the effectiveness and safety of clonidine and guanfacine compared with prazosin for the treatment of PTSD-related nightmares.
Methods:
This was a retrospective, single-center, medical record review of patients 5 to 17 years old admitted to an inpatient psychiatric unit from January 2015 to September 2021. Patients with a new initiation of an alpha-2 agonist (clonidine or guanfacine) or an alpha-1 antagonist (prazosin) with a diagnosis of PTSD, other trauma- or stressor-related disorder or unspecified anxiety disorder were included. The primary endpoint was the percentage of patients with a decrease in the frequency of nightmares.
Results:
A total of 59 patients were included in the study: 37 in the alpha-2 agonist group and 22 in the alpha-1 antagonist group. There was no statistically significant difference in reduction of nightmares with both groups having a high percentage of patients showing response (alpha-2 agonist: 91.9%, alpha-1 antagonist: 86.4%). Time to decrease in nightmares was comparable between groups with a relatively quick onset. Within the alpha-2 agonist group, clonidine (1.59 ± 1.06 days) compared with guanfacine (3.18 ± 1.74 days) had a statistically significant faster time to reduction in nightmares (p = .005).
Discussion:
Both pharmacologic classes of medications were effective treatment options for pediatric PTSD-associated nightmares with a low incidence of adverse effects. There was a quick time to onset seen with all agents.
More Related Videos
08:29Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
Published on: October 10, 2012
09:55Use of a Psychophysiological Script-driven Imagery Experiment to Study Trauma-related Dissociation in Borderline Personality Disorder
Published on: March 8, 2018
Related Concept Videos
Nightmares and Night Terrors
Nightmares...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Cause and Effect
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Post-traumatic Stress Disorder
Symptoms and Behavioral Manifestations
A spectrum of distressing symptoms characterizes PTSD. Recurrent flashbacks, where individuals involuntarily relive traumatic events,...
Management of Insomnia